BORTEZOMIB (VEL) BASED REGIMENS IN MULTIPLE MYELOMA (MM) PATIENTS WITH RENAL IMPAIRMENT (RI): A PRELIMINARY RETROSPECTIVE ITALIAN MULTICENTER STUDY

被引：0
|
作者：
Gentile, M. [1 ]
Ciolli, S. [2 ]
Petrucci, M. T. [3 ]
Galimberti, S. [4 ]
Mele, G. [5 ]
Casulli, A. F.
Mannina, D. [6 ]
Piro, E. [7 ]
Morabito, F. [1 ]
机构：
[1] Ematol Cosenza, Cosenza, Italy
[2] Univ & Osped Careggi, Dipartimento Ematol, Florence, Italy
[3] Univ Roma La Sapienza, Dipartimento Biotecnol & Ematol, Rome, Italy
[4] Osped Santa Chiara, Sez Ematol, Dipartimento Oncol, Pisa, Italy
[5] Presidio Osped A Perrino, Div Ematol, Brindisi, Italy
[6] Azienda Osped Papardo, Div Ematol, Taranto, Italy
[7] Osped Pugliese Ciaccio, Div Ematol, Catanzaro, Italy
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2008年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0210
引用
收藏
页码：84 / 84
页数：1
相关论文
共 50 条
  • [31] Incidence of renal impairment (RI) in multiple myeloma (MM) patients receiving combination chemotherapy and thalidomide (Thal) with bisphosphonate therapy.
    Latif, T
    Elson, P
    Karam, MA
    Reed, J
    Tahir, K
    Srkalovic, G
    Hussein, MA
    BLOOD, 2003, 102 (11) : 687A - 687A
  • [32] Renal Response of Pomalidomide with Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: A Prospective, Open-Label, Multicenter, Phase 2 Study
    Jian, Yuan
    Chang, Long
    Shi, Mingxia
    Sun, Ying
    Chu, Xiaoxia
    Xue, Hua
    Huang, Wenrong
    Shen, Xuliang
    Ma, Jie
    Jia, Guorong
    Peng, Yaqing
    Xi, Zhenfang
    Zhao, Yanhong
    Ma, Yanping
    Xiao, Jing
    Ma, Guangyu
    Wang, Qingming
    Bao, Li
    Dong, Yujun
    Zhou, Hebing
    Sun, Chunyan
    Su, Guohong
    Yan, Yan
    Qimuge, Saiyin
    Su, Liping
    Sun, Jingnan
    Tian, Weiwei
    Sun, Xiuli
    Jing, Hongmei
    Gao, Da
    Chen, Wenming
    Li, Jian
    Gao, Wen
    BLOOD, 2022, 140 : 10167 - 10169
  • [33] A Multicenter Observational Retrospective Study of Second-Line Treatment With Daratumumab-Bortezomib-Dexamethasone (DaraVd) in Multiple Myeloma (MM) Patients Refractory to Lenalidomide
    Rizzello, Ilaria
    Sacchetti, Ilaria
    Barbato, Simona
    Solli, Vincenza
    Stefanoni, Paola
    Cani, Lorenzo
    Pavan, Laura
    Quaresima, Micol
    Belotti, Angelo
    Sgherza, Nicola
    Gentile, Massimo
    Barila, Gregorio
    Patriarca, Francesca
    Celli, Melania
    Vincelli, Iolanda Donatella
    Mancuso, Katia
    Sartor, Chiara
    Pantani, Lucia
    Tacchetti, Paola
    Talarico, Marco
    Puppi, Michele
    Bigi, Flavia
    Cavo, Michele
    Zamagni, Elena
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S275 - S275
  • [34] Effects of bortezomib on the prognosis of the newly-diagnosed multiple myeloma patients with renal impairment
    Yang, Guangzhong
    Wang, Jing
    Fu, Lina
    Shen, Man
    Jiang, Luan
    Zhang, Yong
    Huang, Zhongxia
    Gao, Wen
    Zhang, Lei
    Wu, Yin
    Li, Lihong
    Chen, Wenming
    AFRICAN JOURNAL OF PHARMACY AND PHARMACOLOGY, 2012, 6 (11): : 793 - 797
  • [35] Bortezomib and Dexamethasone Therapy for Newly Diagnosed Patients With Multiple Myeloma Complicated by Renal Impairment
    Li, Jian
    Zhou, Dao-Bin
    Jiao, Li
    Duan, Ming Hui
    Zhang, Wei
    Zhao, Yong Qiang
    Shen, Ti
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 (05): : 394 - 398
  • [36] Lenalidomide plus bortezomib (Rev-Vel) in relapsed and/or refractory multiple myeloma (MM): Final results of a multicenter phase 1 trial.
    Richardson, Paul G.
    Jagannath, S.
    Avigan, D. E.
    Alsina, M.
    Schlossman, R. L.
    Mazumder, A.
    Munshi, N. C.
    Ghobrial, I.
    Doss, D.
    McKenney, M. L.
    Farrell, M. G.
    Warren, D. L.
    Lunde, L. E.
    Gourley, B.
    Vaccaro, S.
    Delaney, C.
    Pountney, S.
    Mitsiades, C. S.
    Hideshima, T.
    Byrne, C.
    Knight, R.
    Birner, A.
    Myers, T.
    Weller, E.
    Anderson, K. C.
    BLOOD, 2006, 108 (11) : 124A - 124A
  • [37] The impact of the introduction of bortezomib on dialysis independence in multiple myeloma patients with renal impairment: a nationwide Dutch population-based study
    Oortgiesen, Berdien E.
    Azad, Roshna
    Hemmelder, Marc H.
    Kibbelaar, Robby E.
    Veeger, Nic J. G. M.
    de Vries, Joost C.
    van Roon, Eric N.
    Hoogendoorn, Mels
    HAEMATOLOGICA, 2018, 103 (07) : E311 - E314
  • [38] Pegylated Liposomal Doxorubicin in Vindesine-Based and Bortezomib-Based Regimens for Patients With Newly Diagnosed Multiple Myeloma: A Retrospective Study of Efficacy and Safety
    Zhai, Yujia
    Yuan, Dai
    Ge, Xueling
    Hu, Shunfeng
    Li, Peipei
    Fang, Xiaosheng
    Li, Ying
    Zhou, Xiangxiang
    Wang, Xin
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [39] Renal Response of Selinexor, Pomalidomide, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: A Prospective, Open-Label, Multicenter, Phase 2 Study
    Zhou, Huixing
    Chang, Long
    Jia, Jing
    Ma, Jie
    Xue, Hua
    Li, Hao
    Huang, Wenrong
    Zhou, Hebing
    Sun, Jingnan
    Su, Liping
    Ma, Yanping
    Huang Hongming
    Jing, Hongmei
    Li, Zhenling
    Ma, Guangyu
    Su, Guohong
    Zhou, Jihao
    Chen, Biyun
    Bao, Li
    Zhang, Zhihua
    BLOOD, 2023, 142
  • [40] RETROSPECTIVE ANALYSIS OF RENAL PATHOLOGY AND CYTOGENETIC EXAMINATION IN PATIENTS WITH MULTIPLE MYELOMA WITH RENAL IMPAIRMENT
    Chen, Ying
    Lyu, Jia
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 : 438 - 438
12345